Kodiak Sciences Inc logo

Kodiak Sciences Inc

KOD
Healthcare|Biotechnology|USA
$41.28
+1.23 (+3.07%)
Tangible Book
$1.80

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 47.9, 236.31, 497.93, 870.81 ], "ebit_estimate": [ -245.42, -227.18, -74.26, 103.32, 399.18 ], "ebitda_estimate": [ -244.58, -224.05, -37.72, null, null ], "net_income_estimate": [ -240.72, -221.07, -67.06, 107.66, 367.07 ], "per_share_eps_estimate": [ -3.75, -3.12, -0.86, 1.17, 4.01 ], "eps_nri_estimate": [ -3.74, -3.12, -0.86, 1.17, 4.01 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.51, 4.18, 4.72, null, null ], "pretax_income_estimate": [ -240.72, -221.07, -67.06, 111.66, 414.36 ], "operating_cash_flow_per_share_estimate": [ -3.31, -2.76, -0.38, null, null ], "roa_estimate": [ -79.7, -83, null, null, null ], "roe_estimate": [ -168.99, -214.03, -9.97, null, null ], "gross_margin_estimate": [ null, 87.5, 89.08, null, null ], "operating_cash_flow_estimate": [ -204.44, -170.73, -23.51, null, null ], "pettm_estimate": [ 0, 0, 0, 35.43, 10.31 ], "long_term_growth_rate_mean": 39.56, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 39.57, "future_eps_nri_estimate_growth": 39.56, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 29.71, "future_ebitda_estimate_growth": 41.28, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 31.49, "future_pretax_income_estimate_growth": 31.49, "future_book_value_per_share_estimate_growth": 22.44, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 54.56, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 44.58 }
quarterly
{ "date": [ "202606", "202609", "202612", "202712" ], "revenue_estimate": [ null, null, null, null ], "ebit_estimate": [ -60.34, -61.82, -63.43, null ], "ebitda_estimate": [ -60.07, -62.21, -64.55, null ], "net_income_estimate": [ -59.22, -60.82, -62.32, -64.95 ], "per_share_eps_estimate": [ -0.96, -0.92, -0.93, null ], "eps_nri_estimate": [ -0.96, -0.93, -0.92, null ], "dividend_estimate": [ null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null ], "pretax_income_estimate": [ -59.22, -60.82, -62.32, -64.95 ], "operating_cash_flow_per_share_estimate": [ -0.92, -0.86, -0.86, null ], "roa_estimate": [ null, null, null, null ], "roe_estimate": [ null, null, null, null ], "gross_margin_estimate": [ null, null, null, null ], "operating_cash_flow_estimate": [ -56.91, -53.2, -53.2, null ], "pettm_estimate": [ null, null, null, null ], "long_term_growth_rate_mean": 39.56, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 39.57, "future_eps_nri_estimate_growth": 39.56, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 29.71, "future_ebitda_estimate_growth": 41.28, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 31.49, "future_pretax_income_estimate_growth": 31.49, "future_book_value_per_share_estimate_growth": 22.44, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 54.56, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 44.58 }